The Impact of Air Travel on Passenger Cognitive Functions

NCT04802785 · Status: UNKNOWN · Phase: PHASE2/PHASE3 · Type: INTERVENTIONAL · Enrollment: 50

Last updated 2021-03-17

No results posted yet for this study

Summary

In the period from June 2021 to June 2022, a prospective clinical study will be conducted in the Republic of Kazakhstan with economy class passengers traveling by plane with a minimum flight period of 5-7 flight hours in the territory of the Republic of Kazakhstan.

Conditions

  • Air Travel

Interventions

DRUG

Citicoline

Citicoline 500 mg (Vitaae®) per os

DRUG

Cytochrome C6

Cytochrome10 mg per os

DRUG

Sodium Chloride Oral Product

Sodium Chloride (NaCl) 2.6 g. per os

DRUG

Potassium Chloride Oral Product

Potassium Chloride 1.5 g per os

DRUG

Sodium Citrate Oral Product

Sodium Citrate 2.90 g per os

DRUG

Dextrose Oral Tablet, Chewable

Dextrose 13.5 g per os

DRUG

Domperidone Oral Product

Domperidone 1 tablet per os

DRUG

Simethicone

3-4 capsules per os

DRUG

Acetylsalicylic acid

Acetylsalicylic acid 150 mg per os

DRUG

Magnesium hydroxide

magnesium hydroxide 30 mg per os

DRUG

Probiotic Formula

1 capsule per os.

DRUG

Melatonin 5 mg

Melatonin 5 mg per os.

Sponsors & Collaborators

  • Dinara Zhumanbayeva

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
20 Years
Max Age
30 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2021-06-30
Primary Completion
2021-07-31
Completion
2022-05-31

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04802785 on ClinicalTrials.gov